Background Etanercept, which blocks the action of tumor necrosis factor, reduces disease
activity in patients with long-standing rheumatoid arthritis. Its efficacy in reducing disease …

Background Tumor necrosis factor (TNF) is a proinflammatory cytokine involved in the
pathogenesis of rheumatoid arthritis, and antagonism of TNF may reduce the activity of the disease…

Background: In a phase II study, etanercept (recombinant human tumor necrosis factor
receptor [p75]:Fc fusion protein) safely produced rapid, dose-dependent improvement in …

Objective To compare the clinical and radiographic outcomes in patients with rheumatoid
arthritis (RA) who received monotherapy with either etanercept or methotrexate (MTX) for 2 …

ContextIn vitro studies have shown that celecoxib inhibits cyclooxygenase 2 (COX-2) but not
COX-1, suggesting that this drug may have anti-inflammatory and analgesic activity without …

Objective To assess the efficacy, safety, and tolerability of etoricoxib, a cyclooxygenase 2 (COX‐2)
selective inhibitor, administered continuously over 52 weeks for the treatment of …

ContextOsteoarthritis (OA) is often treated with nonsteroidal anti-inflammatory drugs (NSAIDs),
acetaminophen, or specific inhibitors of cyclooxygenase 2 (COX-2).ObjectiveTo assess …

The incidence and prevalence of gout are rising, likely as a result of a changing pattern of
risk factors. At-risk populations are growing, due to the fact that people are living longer. …

Objective: To compare the effectiveness and tolerability of three misoprostol dosing regimens
for the prevention of gastric and duodenal ulcers associated with long-term nonsteroidal …

Objective. To examine the sensitivity and positive predictive value of Medicare physician
claims for select rheumatic conditions managed in rheumatology specialty practices. Methods. …